{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:37:37Z","timestamp":1773419857223,"version":"3.50.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-025-00804-x","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T09:58:05Z","timestamp":1763373485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Abnormalities of hemostasis in sickle cell patients and predisposition to thrombotic risk: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2867-0538","authenticated-orcid":false,"given":"Romaric De Manfouo","family":"Tuono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josu\u00e9 Louokdom","family":"Simo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryline Seuko","family":"Njopwouo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude Tagny","family":"Tayou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"804_CR1","doi-asserted-by":"publisher","first-page":"e1609","DOI":"10.1002\/hsr2.1609","volume":"6","author":"DMR Tuono","year":"2023","unstructured":"Tuono DMR, Louokdom JS, Pieme CA, Claude B, Prosper C, Biapa C, et al. Homozygote drepanocytosis: ferric status and inflammation in the world and Africa : review Article and meta analysis. Health Sci Rep. 2023;6:e1609. https:\/\/doi.org\/10.1002\/hsr2.1609.","journal-title":"Health Sci Rep"},{"key":"804_CR2","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1182\/bloodadvances.2019000193","volume":"3","author":"M Nasimuzzaman","year":"2019","unstructured":"Nasimuzzaman M, Malik P. Role of the coagulation system in the pathogenesis of sickle cell disease. Blood Adv. 2019;3:3170\u201380.","journal-title":"Blood Adv"},{"key":"804_CR3","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1182\/blood.2022017074","volume":"141","author":"EM Sparkenbaugh","year":"2023","unstructured":"Sparkenbaugh EM, Henderson MW, Miller-Awe M, Abrams C, Ilich A, Trebak F, et al. Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease. Blood. 2023;141:1871\u201383.","journal-title":"Blood"},{"key":"804_CR4","doi-asserted-by":"publisher","unstructured":"Bhagat S, Thakur AS. Influence of \u03b2-globin haplotypes on oxidative stress, antioxidant capacity and inflammation in sickle cell patients of Chhattisgarh. Indian J Clin Biochem [Internet]. Springer India; 2019;34:201\u20136. Available from: https:\/\/doi.org\/10.1007\/s12291-017-0729-3","DOI":"10.1007\/s12291-017-0729-3"},{"key":"804_CR5","unstructured":"Meher S, Mohanty PK, Patel S, Das K, Sahoo S, Dehury S, et al. Haptoglobin genotypes associated with vaso-occlusive crisis in sickle cell anemia patients of Eastern India. Volume 0. Hemoglobin. Taylor & Francis; 2020. pp. 1\u20137."},{"key":"804_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/01.mbc.0000164431.98169.8f","volume":"16","author":"JS Mohan","year":"2005","unstructured":"Mohan JS, Lip GYH, Wright J, Bareford D, Blann AD. Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to genotype and to inflammation. Blood Coagul Fibrinolysis. 2005;16:209\u201314.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"804_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1365-2796.1993.tb01000.x","volume":"233","author":"CC Hedo","year":"1993","unstructured":"Hedo CC, Aken\u2019ova YA, Okpala IE, Durojaiye AO, Salimonu LS. Acute phase reactants and severity of homozygous sickle cell disease. J Intern Med. 1993;233:467\u201370.","journal-title":"J Intern Med"},{"key":"804_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.22206","volume":"87","author":"DF Noubouossie","year":"2012","unstructured":"Noubouossie DF, L\u00ea PQ, Corazza F, Debaugnies F, Rozen L, Ferster A, et al. Thrombin generation reveals high procoagulant potential in the plasma of sickle cell disease children. Am J Hematol. 2012;87:145\u20139.","journal-title":"Am J Hematol"},{"key":"804_CR9","doi-asserted-by":"publisher","unstructured":"Noubouossie D, Key NS, Ataga KI. Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev [Internet]. Elsevier Ltd; 2016;30:245\u201356. Available from: https:\/\/doi.org\/10.1016\/j.blre.2015.12.003","DOI":"10.1016\/j.blre.2015.12.003"},{"key":"804_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/asheducation-2007.1.91","volume":"2","author":"KI Ataga","year":"2007","unstructured":"Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematol Am Soc Hematol Educ Program. 2007;2:91\u20136.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"804_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ajh.10021","volume":"94","author":"MP Westerman","year":"2002","unstructured":"Westerman MP, Green D, Beaman K, Freels S, Boggio L, Allen S, et al. Coagulation changes in individuals with sickle cell trait. Am J Hematol. 2002;94:89\u201394.","journal-title":"Am J Hematol"},{"key":"804_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1067\/mlc.2001.115450","volume":"137","author":"A Tomer","year":"2001","unstructured":"Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med. 2001;137:398\u2013407.","journal-title":"J Lab Clin Med"},{"key":"804_CR13","first-page":"571","volume":"111","author":"RBJ Francis","year":"1988","unstructured":"Francis RBJ. Protein S deficiency in sickle cell anemia. J Lab Clin Med United States. 1988;111:571\u20136.","journal-title":"J Lab Clin Med United States"},{"key":"804_CR14","first-page":"169","volume":"71","author":"M Peters","year":"1994","unstructured":"Peters M, Plaat BE, ten Cate H, Wolters HJ, Weening RS, Brandjes DP. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost Ger. 1994;71:169\u201372.","journal-title":"Thromb Haemost Ger"},{"key":"804_CR15","first-page":"425","volume":"35","author":"A Marfaing-Koka","year":"1993","unstructured":"Marfaing-Koka A, Boyer-Neumann C, Wolf M, Leroy-Matheron C, Cynober T, Tchernia G. Decreased protein S activity in sickle cell disease. Nouv Rev Fr Hematol Ger. 1993;35:425\u201330.","journal-title":"Nouv Rev Fr Hematol Ger"},{"key":"804_CR16","doi-asserted-by":"publisher","unstructured":"Noubouossie DCF, L\u00ea PQ, Rozen L, Debaugnies F, Ferster A, Demulder A. Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays. Thromb Res [Internet]. Elsevier B.V.; 2012;130:259\u201364. Available from: https:\/\/doi.org\/10.1016\/j.thromres.2011.10.016","DOI":"10.1016\/j.thromres.2011.10.016"},{"key":"804_CR17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood-2012-04-424143","volume":"120","author":"P Chantrathammachart","year":"2012","unstructured":"Chantrathammachart P, Mackman N, Sparkenbaugh E, Wang JG, Parise LV, Kirchhofer D, et al. Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood. 2012;120:636\u201346.","journal-title":"Blood"},{"key":"804_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3324\/haematol.2014.114728","volume":"100","author":"EM Sparkenbaugh","year":"2015","unstructured":"Sparkenbaugh EM, Chantrathammachart P, Wang S, Jonas W, Kirchhofer D, Gailani D, et al. Excess of Heme induces tissue factor-dependent activation of coagulation in mice. Haematologica. 2015;100:308\u201313.","journal-title":"Haematologica"},{"key":"804_CR19","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3324\/haematol.2009.008938","volume":"94","author":"EJ Van Beers","year":"2009","unstructured":"Van Beers EJ, Schaap MCL, Berckmans RJ, Nieuwland R, Sturk A, Van Doormaal FF, et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica. 2009;94:1513\u20139.","journal-title":"Haematologica"},{"key":"804_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1365-2141.2008.07155.x","volume":"142","author":"M Westerman","year":"2008","unstructured":"Westerman M, Pizzey A, Hirschman J, Cerino M, Weil-Weiner Y, Ramotar P, et al. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol. 2008;142:126\u201335.","journal-title":"Br J Haematol"},{"key":"804_CR21","doi-asserted-by":"publisher","unstructured":"Van TLJ, van Heerde WL, Landburg PP, Boderie MJ, Muskiet FAJ, Jacobs N, et al. Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. Biochem Biophys Res Commun [Internet]. Elsevier Inc.; 2009;390:161\u20134. Available from: https:\/\/doi.org\/10.1016\/j.bbrc.2009.09.102","DOI":"10.1016\/j.bbrc.2009.09.102"},{"key":"804_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cca.2019.02.026","volume":"493","author":"SLO Toledo","year":"2019","unstructured":"Toledo SLO, Guedes JVM, Alpoim PN, Rios DRA, de Pinheiro M. Sickle cell disease: hemostatic and inflammatory changes, and their interrelation. Clin Chim Acta. 2019;493:129\u201337.","journal-title":"Clin Chim Acta"},{"key":"804_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/MOH.0b013e328363442f","volume":"20","author":"MY Lim","year":"2013","unstructured":"Lim MY, Ataga KI, Key NS. Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol. 2013;20:472\u20137.","journal-title":"Curr Opin Hematol"},{"key":"804_CR24","doi-asserted-by":"crossref","unstructured":"Qari MH, Dier U, Mousa SA. Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease. Clinical and Applied Thrombosis\/Hemostasis. 2012.","DOI":"10.1177\/1076029611420992"},{"key":"804_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3324\/haematol.11763","volume":"93","author":"KI Ataga","year":"2008","unstructured":"Ataga KI, Moore CG, Hillery CA, Jones S, Whinna HC, Strayhorn D, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica. 2008;93:20\u20136.","journal-title":"Haematologica"},{"key":"804_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1684\/ecn.2013.0328","volume":"24","author":"B Keikhaei","year":"2013","unstructured":"Keikhaei B, Mohseni AR, Norouzirad R, Alinejadi M, Ghanbari S, Shiravi F, et al. Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition. Eur Cytokine Netw. 2013;24:45\u201352.","journal-title":"Eur Cytokine Netw"},{"key":"804_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/10739680490278402","volume":"11","author":"RP Hebbel","year":"2004","unstructured":"Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation United States. 2004;11:129\u201351.","journal-title":"Microcirculation United States"},{"key":"804_CR28","doi-asserted-by":"publisher","unstructured":"Smith RA, Mankelow TJ, Drizou D, Bullock T, Latham T, Trompeter S, et al. Large red cell-derived membrane particles are major contributors to hypercoagulability in sickle cell disease. Sci Rep [Internet]. Nature Publishing Group UK; 2021;11:1\u20139. Available from: https:\/\/doi.org\/10.1038\/s41598-021-90477-z","DOI":"10.1038\/s41598-021-90477-z"},{"key":"804_CR29","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1111\/jth.13416","volume":"14","author":"MF Whelihan","year":"2016","unstructured":"Whelihan MF, Lim MY, Mooberry MJ, Piegore MG, Ilich A, Wogu A, et al. Thrombin generation and cell-dependent hypercoagulability in sickle cell disease. J Thromb Haemost. 2016;14:1941\u201352.","journal-title":"J Thromb Haemost"},{"key":"804_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21155279","volume":"21","author":"MA Lizarralde-Iragorri","year":"2020","unstructured":"Lizarralde-Iragorri MA, Shet AS. Sickle cell disease: A paradigm for venous thrombosis pathophysiology. Int J Mol Sci. 2020;21:1\u201320.","journal-title":"Int J Mol Sci"},{"key":"804_CR31","unstructured":"Amira J, Souheil Z, Takoua M, Samia A, Jalila BK, Mohamed B. Pulmonary embolism in patients with sickle cell disease in intensive care unit: a challenging diagnosis. Ann Intensive Care [Internet]. 2018;8:760\u20136. Available from: https:\/\/www.embase.com\/search\/results?subaction=viewrecord%26id=L620836872%26from=export U2 - L620836872."},{"issue":"3","key":"804_CR32","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/j.1537-2995.2012.03765.x","volume":"53","author":"OF Richard","year":"2013","unstructured":"Richard OF, Jeffrey J, Jeanne EH, James CZ, Eldad AH, Steven LS. Frequency of glucose-6-phosphate dehydrogenase deficient packed red blood cell units in a metropolitan transfusion service. Transfusion. 2013;53(3):606\u201311. https:\/\/doi.org\/10.1111\/j.1537-2995.2012.03765.x.","journal-title":"Transfusion"},{"issue":"12","key":"804_CR33","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1111\/jth.12744","volume":"12","author":"PN Rakhi","year":"2014","unstructured":"Rakhi PN, Michael BS, Bailey J, Carlton H, Jodi BS, Sophie L. Venous thromboembolism incidence in the cooperative study of sickle cell disease. J Thromb Haemost. 2014;12(12):2010\u20136. https:\/\/doi.org\/10.1111\/jth.12744.","journal-title":"J Thromb Haemost"},{"key":"804_CR34","doi-asserted-by":"publisher","unstructured":"Marshall C, Brereton P, Systematic Review Toolbox. A catalogue of tools to support systematic reviews systematic review toolbox : A catalogue of tools to support systematic reviews. 2015; https:\/\/doi.org\/10.1145\/2745802.2745824","DOI":"10.1145\/2745802.2745824"},{"key":"804_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41073-018-0061-3","volume":"4","author":"C Baethge","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA\u2014a scale for the quality assessment of narrative review articles. Res Integr Peer Rev Res Integr Peer Rev. 2019;4:1\u20138.","journal-title":"Res Integr Peer Rev Res Integr Peer Rev"},{"key":"804_CR36","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Morgan RL, Rooney AA, Taylor KW, Thayer KA, Silva RA, et al. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). Environ Int. 2024;186.","DOI":"10.1016\/j.envint.2024.108602"},{"key":"804_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jth.13839","volume":"16","author":"JJ Noubiap","year":"2018","unstructured":"Noubiap JJ, Temgoua MN, Tankeu R, Tochie JN, Wonkam A, Bigna JJ. Sickle cell disease, sickle trait and the risk for venous thromboembolism: A systematic review and meta-analysis. Thromb J Thromb J. 2018;16:1\u20138.","journal-title":"Thromb J Thromb J"},{"key":"804_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12288-016-0701-z","volume":"33","author":"M Chekkal","year":"2017","unstructured":"Chekkal M, Rahal MCA, Moulasserdoun K, Seghier F. Increased level of factor VIII and physiological inhibitors of coagulation in patients with sickle cell disease. Indian J Hematol Blood Transfus Springer India. 2017;33:235\u20138.","journal-title":"Indian J Hematol Blood Transfus Springer India"},{"key":"804_CR39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/1076029611420992","volume":"18","author":"MH Qari","year":"2012","unstructured":"Qari MH, Dier U, Mousa SA. Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease. Clin Appl Thromb. 2012;18:195\u2013200.","journal-title":"Clin Appl Thromb"},{"key":"804_CR40","doi-asserted-by":"crossref","unstructured":"Belhaj Nefissi R, Doggui R, Ouali F, Messaoud T, Gritli N, Factor V, Leiden. G1691A, prothrombin G20210A, and MTHFR C677T and A1298C mutations in patients with sickle cell disease in Tunisia. Volume 42. Hemoglobin. Informa Healthcare USA, Inc; 2018. pp. 96\u2013102.","DOI":"10.1080\/03630269.2018.1451340"},{"key":"804_CR41","first-page":"268","volume":"60","author":"P Papadogeorgou","year":"2024","unstructured":"Papadogeorgou P, Valsami S, Boutsikou M, Pergantou E, Mantzou A, Papassotiriou I, et al. Coagulation profile in neonates with congenital heart disease: A pilot study. Med (B Aires). 2024;60:268.","journal-title":"Med (B Aires)"},{"key":"804_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1179\/2046905511Y.0000000009","volume":"32","author":"AWM Al-Saqladi","year":"2012","unstructured":"Al-Saqladi AWM, Bin-Gadeem HA, Brabin BJ. Utility of plasma transferrin receptor, ferritin and inflammatory markers in children with sickle cell disease. Paediatr Int Child Health. 2012;32:27\u201334.","journal-title":"Paediatr Int Child Health"},{"key":"804_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:1\u201313.","journal-title":"BMC Med Res Methodol"},{"key":"804_CR44","doi-asserted-by":"crossref","unstructured":"Andrade C. Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets. J Clin Psychiatry United States; 2020;81.","DOI":"10.4088\/JCP.20f13681"},{"key":"804_CR45","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/jrsm.1547","volume":"13","author":"CB Migliavaca","year":"2022","unstructured":"Migliavaca CB, Stein C, Colpani V, Barker TH, Ziegelmann PK, Munn Z, et al. Meta-analysis of prevalence: I(2) statistic and how to deal with heterogeneity. Res Synth Methods Engl. 2022;13:363\u20137.","journal-title":"Res Synth Methods Engl"},{"key":"804_CR46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/1119-3077.110132","volume":"16","author":"JM Chinawa","year":"2013","unstructured":"Chinawa JM, Emodi IJ, Ikefuna AN, Ocheni S. Coagulation profile of children with sickle cell anemia in steady state and crisis attending the university of Nigeria teaching hospital, Ituku-Ozalla, Enugu. Niger J Clin Pract. 2013;16:159\u201363.","journal-title":"Niger J Clin Pract"},{"key":"804_CR47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/03630260601059217","volume":"31","author":"FI Buseri","year":"2007","unstructured":"Buseri FI, Shokunbi WA, Jeremiah ZA. Plasma fibrinogen levels in Nigerian homozygous (Hb SS) sickle cell patients. Hemoglobin. 2007;31:89\u201392.","journal-title":"Hemoglobin"},{"key":"804_CR48","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/10245330600841287","volume":"11","author":"F Buseri","year":"2006","unstructured":"Buseri F, Jeremiah ZA, Shokunbi WA. Plasma levels of some blood coagulation parameters in Nigerian homozygous sickle cell patients (HbSS) in steady state. Hematology. 2006;11:375\u20139.","journal-title":"Hematology"},{"key":"804_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11604\/pamj.2014.19.289.4451","volume":"19","author":"MD Ajuwon","year":"2014","unstructured":"Ajuwon MD, Olayemi E, Benneh AA. Plasma levels of some coagulation parameters in steady state HBSC disease patients. Pan Afr Med J. 2014;19:1\u20135.","journal-title":"Pan Afr Med J"},{"key":"804_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12185-013-1392-y","volume":"98","author":"ES Hatzipantelis","year":"2013","unstructured":"Hatzipantelis ES, Pana ZD, Gombakis N, Taparkou A, Tzimouli V, Kleta D, et al. Endothelial activation and inflammation biomarkers in children and adolescents with sickle cell disease. Int J Hematol. 2013;98:158\u201363.","journal-title":"Int J Hematol"},{"key":"804_CR51","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/ajh.20052","volume":"76","author":"JB Schnog","year":"2004","unstructured":"Schnog JB, Mac Gillavry MR, Van Zanten AP, Meijers JCM, Rojer RA, Duits AJ, et al. Protein C and S and inflammation in sickle cell disease. Am J Hematol. 2004;76:26\u201332.","journal-title":"Am J Hematol"},{"key":"804_CR52","doi-asserted-by":"crossref","unstructured":"Bayazit AK, Kilin\u00e7 Y. Natural coagulation inhibitors (protein C, protein S, antithrombin) in patients with sickle cell anemia in a steady state. Pediatr Int. 2001;43:592\u20136.","DOI":"10.1046\/j.1442-200X.2001.01476.x"},{"key":"804_CR53","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3324\/haematol.2014.114587","volume":"100","author":"MP Colella","year":"2015","unstructured":"Colella MP, de Paula EV, Machado-Neto JA, Conran N, Annichino-Bizzacchi JM, Costa FF, et al. Elevated hypercoagulability markers in hemoglobin SC disease. Haematologica. 2015;100:466\u201371.","journal-title":"Haematologica"},{"key":"804_CR54","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/bjh.13641","volume":"171","author":"C Amin","year":"2015","unstructured":"Amin C, Adam S, Mooberry MJ, Kutlar A, Kutlar F, Esserman D, et al. Coagulation activation in sickle cell trait: an exploratory study. Br J Haematol. 2015;171:638\u201346.","journal-title":"Br J Haematol"},{"key":"804_CR55","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood.V98.12.3228","volume":"98","author":"BN Yamaja Setty","year":"2001","unstructured":"Yamaja Setty BN, Koneti Rao A, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood. 2001;98:3228\u201333.","journal-title":"Blood"},{"key":"804_CR56","first-page":"266","volume":"13","author":"LAM Bashawri","year":"2007","unstructured":"Bashawri LAM, Al-Mulhim AA, Ahmed MA, Bahnassi AA. Platelet aggregation and physiological anticoagulants in sickle-cell disease. East Mediterr Heal J. 2007;13:266\u201372.","journal-title":"East Mediterr Heal J"},{"key":"804_CR57","doi-asserted-by":"publisher","unstructured":"Shome D, Al-Jamea L, Woodman A, Salem AH, Bakhiet M, Taha S, et al. Plasminogen activator inhibitor-2 and impaired fibrinolysis in pregnancy and sickle cell anemia. Arch Gynecol Obstet [Internet]. Springer Berlin Heidelberg; 2024;309:2447\u201358. Available from: https:\/\/doi.org\/10.1007\/s00404-023-07121-6","DOI":"10.1007\/s00404-023-07121-6"},{"key":"804_CR58","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3233\/CH-189013","volume":"68","author":"C Faes","year":"2018","unstructured":"Faes C, Sparkenbaugh EM, Pawlinski R. Hypercoagulable state in sickle cell disease. Clin Hemorheol Microcirc. 2018;68:301\u201318.","journal-title":"Clin Hemorheol Microcirc"},{"key":"804_CR59","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11239-007-0177-7","volume":"25","author":"AD Blann","year":"2008","unstructured":"Blann AD, Mohan JS, Bareford D, Lip GYH. Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease: relationship to genotype. J Thromb Thrombolysis. 2008;25:185\u20139.","journal-title":"J Thromb Thrombolysis"},{"key":"804_CR60","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.freeradbiomed.2007.08.014","volume":"43","author":"M Aslan","year":"2007","unstructured":"Aslan M, Freeman BA. Redox-dependent impairment of vascular function in sickle cell disease. Free Radic Biol Med. 2007;43:1469\u201383.","journal-title":"Free Radic Biol Med"},{"key":"804_CR61","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1111\/jth.13717","volume":"15","author":"E Sparkenbaugh","year":"2017","unstructured":"Sparkenbaugh E, Pawlinski R. Prothrombotic aspects of sickle cell disease. J Thromb Haemost. 2017;15:1307\u201316.","journal-title":"J Thromb Haemost"},{"key":"804_CR62","doi-asserted-by":"crossref","unstructured":"Bandeira ICJ, Rocha LBS, Barbosa MC, Elias DBD, Querioz JAN, Freitas MVC, et al. Chronic inflammatory state in sickle cell anemia patients is associated with HBB*S haplotype. Cytokine. Volume 65. Elsevier Ltd; 2014. pp. 217\u201321.","DOI":"10.1016\/j.cyto.2013.10.009"},{"key":"804_CR63","unstructured":"Mehta SR, Afenyi-Annan A, Byrns PJ, Lottenberg R. Opportunities to improve outcomes in sickle cell disease. Am Fam Physician. 2006;74."},{"key":"804_CR64","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1055\/s-0031-1273087","volume":"37","author":"L De Franceschi","year":"2011","unstructured":"De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. Semin Thromb Hemost. 2011;37:226\u201336.","journal-title":"Semin Thromb Hemost"},{"key":"804_CR65","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/ajh.10178","volume":"71","author":"JB Schnog","year":"2002","unstructured":"Schnog JB, Mac Gillavry MR, Rojer RA, Meijers JCM, Fijnheer R, Ten Cate H, et al. No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease. Am J Hematol. 2002;71:53\u20135.","journal-title":"Am J Hematol"},{"key":"804_CR66","doi-asserted-by":"crossref","unstructured":"An R, Man Y, Cheng K, Zhang T, Chen C, Wang F, et al. Sickle red blood cell- \u00ad derived extracellular vesicles activate endothelial cells and enhance sickle red cell adhesion mediated by von Willebrand factor. Br J Haematol. 2023;1\u201312.","DOI":"10.1101\/2022.05.25.492883"},{"issue":"2","key":"804_CR67","first-page":"123","volume":"4","author":"NE Omer","year":"2009","unstructured":"Omer NE, Satti MMH, Mohamed AO. Plasma level of von Willebrand factor: an indicator of severity in sickle cell disease. Sudan J Med Sci. 2009;4(2):123\u20139.","journal-title":"Sudan J Med Sci"},{"key":"804_CR68","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1055\/s-0038-1657624","volume":"78","author":"B Osterud","year":"1997","unstructured":"Osterud B. Tissue factor: a complex biological role. Thromb Haemost Ger. 1997;78:755\u20138.","journal-title":"Thromb Haemost Ger"},{"key":"804_CR69","doi-asserted-by":"crossref","unstructured":"Liesner R, Mackie I, Cookson J, Mcdonald S, Chitolie A, Donohoe S, et al. Prothrombotic changes in children with sickle cell disease: relationships to cerebrovascular disease and transfusion. Br J Haematol. 1998;103:1037\u201344.","DOI":"10.1046\/j.1365-2141.1998.01121.x"},{"key":"804_CR70","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4103\/1596-3519.68363","volume":"9","author":"MA Emokpae","year":"2010","unstructured":"Emokpae MA, Uadia PO, Gadzama AA. Correlation of oxidative stress and inflammatory markers with the severity of sickle cell nephropathy. Ann Afr Med. 2010;9:141\u20136.","journal-title":"Ann Afr Med"},{"key":"804_CR71","first-page":"334","volume":"34","author":"R Crook","year":"2019","unstructured":"Crook R, Wheeler K. Falsely low activated clotting time measured in a patient with sickle cell trait. Perfus (United Kingdom). 2019;34:334\u20136.","journal-title":"Perfus (United Kingdom)"},{"key":"804_CR72","doi-asserted-by":"crossref","unstructured":"Shet AS, Lizarralde-iragorri MA, Naik RP. The molecular basis for the prothrombotic state in sickle cell disease. Haematologica. 2020;105(10):2368\u201379.","DOI":"10.3324\/haematol.2019.239350"},{"key":"804_CR73","doi-asserted-by":"crossref","unstructured":"Ataga KI, Brittain JE, Desai P, May R, Jones S, Delaney J, et al. Association of coagulation activation with clinical complications in sickle cell disease. PLoS ONE. 2012;7.","DOI":"10.1371\/journal.pone.0029786"},{"key":"804_CR74","doi-asserted-by":"crossref","unstructured":"Tuono DMR, Simo LJ, Ngamgwe TPR, Seuko M, Kwetche PR. Hematology and disorders hematological and hemostasis profile, thrombotic risk in sickle cell patient in Cameroon : an analytical cross-sectional study. Hematol Disord. 2024;3(1):1\u201312.","DOI":"10.58489\/2836-3582\/011"},{"key":"804_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0078801","volume":"8","author":"R Colombatti","year":"2013","unstructured":"Colombatti R, De Bon E, Bertomoro A, Casonato A, Pontara E, Omenetto E, et al. Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy. PLoS ONE. 2013;8:1\u20138.","journal-title":"PLoS ONE"},{"key":"804_CR76","doi-asserted-by":"publisher","unstructured":"Gupta S, Carmona R, Malvar J, Young G. Thromboelastographic characterization of the activated clotting system in children with sickle cell trait or sickle cell disease. Thromb Res [Internet]. Elsevier Ltd; 2017;151:44\u201350. Available from: https:\/\/doi.org\/10.1016\/j.thromres.2016.09.017","DOI":"10.1016\/j.thromres.2016.09.017"},{"key":"804_CR77","doi-asserted-by":"publisher","unstructured":"Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood [Internet]. American Society of Hematology. 1998;91:4216\u201323. Available from: https:\/\/doi.org\/10.1182\/blood.V91.11.4216","DOI":"10.1182\/blood.V91.11.4216"},{"key":"804_CR78","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1160\/TH11-10-0689","volume":"107","author":"GT Gerotziafas","year":"2012","unstructured":"Gerotziafas GT, van Dreden P, Chaari M, Galea V, Khaterchi A, Lionnet F, et al. The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with Circulating erythrocyte-derived micro particles. Thromb Haemost. 2012;107:1044\u201352.","journal-title":"Thromb Haemost"},{"key":"804_CR79","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1182\/blood-2006-09-003004","volume":"109","author":"LO Mosnier","year":"2007","unstructured":"Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109:3161\u201372.","journal-title":"Blood"},{"key":"804_CR80","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ajh.2830470409","volume":"47","author":"PA Lane","year":"1994","unstructured":"Lane PA, O\u2019Connell JL, Marlar RA. Erythrocyte membrane vesicles and irreversibly sickled cells bind protein S. Am J Hematol United States. 1994;47:295\u2013300.","journal-title":"Am J Hematol United States"},{"key":"804_CR81","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1046\/j.1365-2141.1997.2663083.x","volume":"98","author":"JG Wright","year":"1997","unstructured":"Wright JG, Malia R, Cooper P, Thomas P, Preston FE, Serjeant GR. Protein C and protein S in homozygous sickle cell disease: does hepatic dysfunction contribute to low levels? Br J Haematol Engl. 1997;98:627\u201331.","journal-title":"Br J Haematol Engl"},{"key":"804_CR82","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.thromres.2005.11.010","volume":"118","author":"DA Lewis","year":"2006","unstructured":"Lewis DA, Nyska A, Potti A, Hoke HA, Klemp KF, Ward SM, et al. Hemostatic activation in a chemically induced rat model of severe hemolysis and thrombosis. Thromb Res. 2006;118:747\u201353.","journal-title":"Thromb Res"},{"key":"804_CR83","doi-asserted-by":"publisher","unstructured":"Miezi M, Nzunzu J, Hayakawa Y, Yamamoto C, Kaji T. Decreased thrombin activity by a Congolese herbal medicine used in sickle cell anemia. J Ethnopharmacol [Internet]. Elsevier; 2013;148:895\u2013900. Available from: https:\/\/doi.org\/10.1016\/j.jep.2013.05.038","DOI":"10.1016\/j.jep.2013.05.038"},{"key":"804_CR84","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/MBC.0b013e32835187f8","volume":"23","author":"AS Lawrie","year":"2012","unstructured":"Lawrie AS, Pizzey A, Trompeter S, Meiselman H, Mohandas N, Dumanski JP, et al. Procoagulant activity in patients with sickle cell trait. Blood Coagul Fibrinolysis. 2012;23:268\u201370.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"804_CR85","first-page":"172","volume":"18","author":"A Tomer","year":"2004","unstructured":"Tomer A. Platelet activation as a marker for in vivo prothrombotic activity: detection by flow cytometry. J Biol Regul Homeost Agents Italy. 2004;18:172\u20137.","journal-title":"J Biol Regul Homeost Agents Italy"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00804-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-025-00804-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00804-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:05:21Z","timestamp":1763424321000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-025-00804-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1186\/s12959-025-00804-x","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Romaric Tuono De Manfouo affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained\u201d.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency statement"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}